Leveraging Salmonella typhi Ty21a to activate innate and adaptive immune responses against cancer cells
Socium Therapeutics is developing an orally administered immunotherapy platform based on recombinant Salmonella typhi Ty21a, the same strain that has been used as the typhoid vaccine since 1989. Socium’s platform – CReST (Cross-presenting Recombinant Salmonella typhi Ty21a) – induces an innate immune response from Salmonella pathogenesis and an adaptive immune response by cross-presenting tumor-specific antigen to enhance activation of killer T-cells.

News

Latest News

Socium Therapeutics Selected to Present at BIO Investor Forum 2018

October 1, 2018 -- Socium Therapeutics has been selected to present at the BIO Investor Forum in San Francisco on October 18, 2018. Tim Salmon, CEO of Socium, commented, "I'm really excited to present in San Francisco. We have been meeting with many venture funds and...

Marcela F. Pasetti, PhD joins Advisory Board of Socium Therapeutics

August 31, 2018 -- Today, Socium Therapeutics announced that Marcela F. Pasetti, PhD joined the company's Scientific Advisory Board. Dr. Pasetti is a Professor at the University of Maryland School of Medicine in the Center for Vaccine Development. Dr. Pasetti...

Anna Ferrari, MD joins Advisory Board of Socium Therapeutics

July 12, 2018 -- Today, Socium Therapeutics announced that Anna Ferrari, MD has joined the company's Scientific Advisory Board. Dr. Ferrari is a medical oncologist and clinical researcher dedicated to prostate cancer research. Her experience includes clinical practice...

Contact

Get InTouch

Email:

info@sociumtherapeutics.com

Phone:

(973) 585-6202

Address:

90 E. Halsey Road
Suite 311
Parsippany, NJ 07054